TrialAnnals of the rheumatic diseases2017

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.

Philip J Mease et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.